Retatrutide vs MOTS-C
Retatrutide (LY3437943) is an investigational single-peptide triple agonist of the GIP, GLP-1 and glucagon receptors, taken through phase 1 and phase 2 randomised trials in obesity, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, with a registrational phase 3 programme described in published design papers and a first phase 3 readout in 2026. MOTS-c is a 16-amino-acid microprotein encoded within the mitochondrial 12S rRNA gene, described as a retrograde signalling molecule acting through AMPK and the folate-methionine one-carbon cycle. The two are set side by side because both are discussed as metabolic interventions and both are sold in the same market. No published study has administered both. One 2026 narrative review of therapeutic peptides names each compound, in separate sections and without comparing them, and that is the entire body of literature engaging the pair. Every other comparison is indirect, drawn from studies that differ in species, endpoint and stage of development.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered retatrutide and MOTS-c in the same experiment, in any species. Searches of PubMed and Europe PMC returned a single publication that engages both: a 2026 narrative review of therapeutic peptides in aesthetic, metabolic and endocrine practice, which discussed each compound in its own section and drew no comparison between them. That review recorded that retatrutide reduced more than a fifth of body weight over 48 weeks in a phase 2 obesity trial and was not approved by the US Food and Drug Administration, and that the MOTS-c data were almost exclusively preclinical, with no approved therapeutic application and no robust evidence in humans. Any comparison between the two is therefore indirect. The retatrutide record consists of randomised, placebo-controlled human trials with body-weight, HbA1c and liver-fat endpoints; interventional MOTS-c data come from rodents and cell culture, and the human MOTS-c literature measures endogenous concentrations rather than testing an administered peptide.
The publication that covers both
- 01Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of therapeutic peptides used in aesthetic, metabolic and endocrine practice, assembled from a keyword search that included GLP-1 agents and MOTS-C, with a summary table of molecular formulae and regulatory status
The review covered both compounds without comparing them and without administering either. It described retatrutide as a tri-hormonal agonist that additionally activates the glucagon receptor, increasing energy expenditure and hepatic lipolysis, and recorded a phase 2 trial in which body weight fell by more than a fifth over 48 weeks, with the compound listed as not yet approved. It described MOTS-c as a mitochondria-encoded signalling peptide with no approved therapeutic application and no late-stage clinical development, stating that the supporting data were almost exclusively preclinical, showed no major signs of toxicity, and lacked robust evidence in humans.
Side by side.
| Retatrutide | MOTS-C | |
|---|---|---|
| Evidence maturity | Clinical | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 13 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic investigational peptide, LY3437943, engineered as a single molecule with balanced agonism at the glucagon, GIP and GLP-1 receptors. It has no endogenous counterpart and was first described in the literature in 2022. | A 16-amino-acid microprotein encoded within the mitochondrial 12S rRNA gene, so the molecule is genuinely endogenous. It was reported in 2015 as a mitochondrial-derived peptide targeting the folate-methionine one-carbon cycle. |
| Mechanism as described in the literature | Receptor pharmacology. In vitro work characterised balanced agonism at three incretin and glucagon receptors, and rodent studies attributed weight reduction to both lower calorie intake and increased energy expenditure. | Retrograde mitochondrial-to-nuclear signalling. Reported effects include AMPK activation, modulation of folate-methionine one-carbon metabolism and nuclear stress-response gene expression, with a 2024 report describing direct binding and activation of casein kinase 2 in skeletal muscle. |
| Size of the evidence base | Large and clinical. Published phase 1, phase 2 and, from 2026, phase 3 randomised controlled trials in obesity and type 2 diabetes, supported by systematic reviews and meta-analyses of those trials and by design papers for the TRIUMPH and TRANSCEND programmes. | Moderate and preclinical. Interventional data come almost entirely from rodent and cell-culture studies; the human record consists of observational biomarker measurements and one genotype-association meta-analysis across East Asian cohorts. |
| Best-characterised finding | Dose-dependent body-weight reduction. In a 48-week phase 2 obesity trial the least-squares mean change in body weight was -24.2% at the highest dose compared with -2.1% with placebo, and liver fat content fell dose-dependently in a phase 2a MASLD substudy. | Prevention of insulin resistance in mice. The 2015 report found that administration prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, and later rodent work reported improved physical performance and improved skeletal muscle mitochondrial bioenergetics. |
| Human data | Randomised, double-blind, placebo-controlled trials in obesity, type 2 diabetes and steatotic liver disease, plus a 2026 phase 3 trial in type 2 diabetes reporting HbA1c reductions against placebo, and post-hoc analyses of kidney, lipid and body-composition endpoints. | No controlled trial has administered exogenous MOTS-c to people. Human studies measured endogenous concentrations in obesity, polycystic ovary syndrome, acute coronary syndrome, heart failure and after exercise or heat exposure, and those concentrations moved in opposite directions across conditions. |
| Safety signals reported | Adverse events across the phase 2 trials were predominantly gastrointestinal and dose-related. Long-term safety, cardiovascular outcome data and durability of effect after discontinuation have not been established in peer-reviewed reports. | No human safety dataset exists, because no dosing study has been published. The 2026 review that names both compounds recorded no major signs of toxicity in the preclinical MOTS-c work while stating that robust human evidence was absent. |
| Regulatory status | Investigational. As of August 2026 the compound was not an approved medicine in any jurisdiction, and the phase 3 obesity, sleep apnoea and osteoarthritis trials had published rationale and design only, with efficacy disclosed as sponsor topline announcements. | Not approved in any jurisdiction and not in late-stage clinical development. No trial administering the peptide to humans has been published or registered, so pharmacokinetics and dosing in people are unestablished. |
| Basis of most marketing claims | Published randomised trial results, although the figures quoted commercially were generated in supervised trials of an unapproved investigational medicine with structured dose escalation. | Extrapolation from rodent and cell-culture experiments, and from observational associations between circulating concentrations and metabolic status, to outcomes that have never been tested in an administered human study. |
And what it does not.
The two compounds sit at opposite ends of the development pipeline, and nothing in the literature compares them. Retatrutide has completed randomised, placebo-controlled trials in obesity, type 2 diabetes and steatotic liver disease, with dose-dependent reductions in body weight, HbA1c and liver fat, and a first phase 3 result published in 2026; its open questions are long-term safety, cardiovascular outcomes and what happens after discontinuation, none of which has been answered in peer-reviewed reports. MOTS-c has an internally consistent preclinical account, covering AMPK activation, mitochondrial bioenergetics and glucose handling in mice, and no human dosing study at all, so pharmacokinetics, safety and any functional effect in people remain unknown. Circulating MOTS-c has been measured in people, but its direction of change differs between conditions and assay methods are not standardised, which limits what the biomarker literature can support. The published record does not establish that the two compounds are interchangeable, complementary or comparable in effect; only one of them has produced a measurable result in a randomised human trial.
Common questions.
- Has any published study given retatrutide and MOTS-c to the same subjects?
No. Searches of PubMed and Europe PMC located no experiment, in humans or animals, that administered both. The only publication engaging the pair is a 2026 narrative review of therapeutic peptides that describes each compound in a separate section, reports no new data and draws no comparison. Because the two literatures were generated in different species, with different endpoints and at different stages of development, any statement about which compound performs better than the other is an inference rather than a published finding.
- What is the strongest published evidence for each compound?
For retatrutide it is randomised controlled trial evidence: a 48-week phase 2 obesity trial reporting a least-squares mean body-weight change of -24.2% at the highest dose against -2.1% with placebo, followed in 2026 by a phase 3 trial in type 2 diabetes reporting HbA1c reductions against placebo. For MOTS-c it is rodent work, principally the 2015 report that administration prevented diet-induced obesity and insulin resistance in mice, and a 2021 study reporting improved physical performance in young, middle-aged and old animals.
- Does the human MOTS-c research show that the peptide works in people?
It does not test that question. The human MOTS-c literature measures endogenous concentrations rather than administering the peptide, so it describes associations rather than effects. Those associations are also inconsistent in direction: circulating MOTS-c has been reported lower in diabetes and in polycystic ovary syndrome, and higher in obesity and acute coronary syndrome. Assay methods differ between studies, and a systematic review of mitochondrial-derived peptides noted small study numbers and heterogeneity. In one cohort, concentrations did not change after surgical weight loss.
- Do the two compounds act on the same biological pathway?
The published mechanisms do not overlap. Retatrutide acts at cell-surface receptors, with characterised agonism at the glucagon, GIP and GLP-1 receptors, and rodent work attributed its effects to reduced calorie intake together with increased energy expenditure. MOTS-c is described as an intracellular and retrograde signal acting on AMPK, on folate-methionine one-carbon metabolism and on nuclear stress-response gene expression, with a 2024 report identifying casein kinase 2 as a direct binding partner. No published study has examined whether the two pathways interact.
- Has either retatrutide or MOTS-c been approved by a regulator?
Neither is. As of August 2026 retatrutide remained investigational, with phase 3 trials in progress and efficacy results for several of them disclosed as sponsor announcements rather than peer-reviewed publications. MOTS-c is not approved anywhere and is not in late-stage clinical development; the 2026 review that names both compounds stated as much, adding that its supporting data were almost exclusively preclinical. Neither compound has an established human dosing regimen for the uses under which the two are marketed.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.